Renin inhibition activity by chitooligosaccharides.
Pyo-Jam Park1, Chang-Bum Ahn, You-Jin Jeon
1Department of Biotechnology, Kunkuk University, Chungju 380-701, Republic of Korea.
Bioorganic & Medicinal Chemistry Letters
|March 4, 2008
Summary
Chitooligosaccharides (COSs) with specific molecular weights and deacetylation degrees show potent renin inhibition. Higher deacetylation and optimized molecular weight enhance COSs
Area of Science:
- Biochemistry
- Food Science
- Pharmacology
Background:
- Renin is a key enzyme in the renin-angiotensin-aldosterone system (RAAS), regulating blood pressure.
- Dysregulation of the RAAS is implicated in various cardiovascular diseases.
- Chitooligosaccharides (COSs) are derived from chitin and possess potential bioactive properties.
Purpose of the Study:
- To investigate the renin inhibition modes of chitooligosaccharides (COSs) with varying molecular weights (MW) and degrees of deacetylation (DD).
- To identify the structural characteristics of COSs that contribute to potent renin inhibitory activity.
Main Methods:
- Preparation of six distinct COS fractions using an ultrafiltration membrane reactor.
- Evaluation of renin inhibition assays for all COS fractions.
- Determination of inhibition kinetics (competitive, non-competitive, mixed) using Lineweaver-Burk and Dixon plots.
Main Results:
- All tested COSs demonstrated dose-dependent renin inhibitory activity.
- COSs with a higher degree of deacetylation (90-COSs) exhibited more potent inhibition compared to those with lower DD (50-COSs).
- A specific 90-MMWCOS fraction (1000-5000 Da) displayed the highest activity (IC50 = 0.51 mg/mL) and acted as a competitive inhibitor (Ki = 0.28 mg/mL).
Conclusions:
- Both the degree of deacetylation (DD) and molecular weight (MW) are critical factors influencing the renin inhibitory activity of COSs.
- Optimized COS structures hold promise as potential therapeutic agents for managing hypertension by targeting the RAAS.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
08:35Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.